Scinai Immunotherapeutics Ltd.
SCNI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $1 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $1 | $1 | $1 | $1 |
| Gross Profit | -$1 | -$1 | -$1 | -$1 |
| % Margin | -88.1% | – | – | – |
| R&D Expenses | $6 | $5 | $6 | $3 |
| G&A Expenses | $0 | $0 | $0 | $8 |
| SG&A Expenses | $3 | $5 | $5 | $8 |
| Sales & Mktg Exp. | $0 | $0 | $0 | -$0 |
| Other Operating Expenses | $0 | -$0 | $0 | -$0 |
| Operating Expenses | $8 | $10 | $11 | $11 |
| Operating Income | -$9 | -$10 | -$11 | -$11 |
| % Margin | -1,312.8% | – | – | – |
| Other Income/Exp. Net | $13 | $3 | $5 | $3 |
| Pre-Tax Income | $5 | -$7 | -$6 | -$8 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | $5 | -$7 | -$6 | -$8 |
| % Margin | 728.9% | – | – | – |
| EPS | 6 | -16.8 | -30.8 | -87.6 |
| % Growth | 135.7% | 45.5% | 64.8% | – |
| EPS Diluted | 6 | -16.8 | -30.8 | -80 |
| Weighted Avg Shares Out | 1 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 1 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $8 | $0 |
| Interest Expense | $1 | $0 | $5 | $3 |
| Depreciation & Amortization | $2 | $1 | $1 | $0 |
| EBITDA | -$7 | -$9 | -$10 | -$10 |
| % Margin | -1,062.2% | – | – | – |